Ertugliflozin
- TRADE NAME: Steglatro (Merck Sharpe & Dohme)
- INDICATIONS: Type II diabetes mellitus
- CLASS: Sodium-glucose co-transporter 2 (SGLT2) inhibitor ('gliflozin')
- HALF-LIFE: 17 hours
FDA APPROVAL DATE: 12/19/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
Not recommended during the second and third trimesters of pregnancy
Contra-indicated in patients with severe renal impairment, end stage renal disease, or on dialysis.
Please login to see the rest of this drug profile
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric